Year of publication: 2021

ACNP 2021

Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole

ASCP 2021

Characterizing the Antipsychotic Activity and Safety Profile of the Novel Muscarinic Agonist KarXT (Xanomeline + Trospium): Primary and Secondary Results From a Phase 2 Placebo-Controlled Trial in Schizophrenia

ASCP 2021

Xanomeline’s Activity in Rodent Models of Psychosis: Role of Central Muscarinic Receptors and Augmentation by Risperidone and Aripiprazole

ECNP 2021

KarXT Treatment Improves Cognitive Performance in Cognitively Impaired Patients with Schizophrenia: A Post hoc Analysis of the Phase 2 EMERGENT-1 Study

ISCTM 2021

Methodological Approaches to Outliers in Cognitive Assessment for Schizophrenia: A Post Hoc Analysis of the EMERGENT-1 Study

NEI Synapse 2021

Understanding Why Muscarinic Receptor Agonists Have Antipsychotic Properties

SIRS 2021

The M1/M4 Agonist Xanomeline in Combination With Trospium Is Effective for Acute Treatment of Schizophrenia: PANSS Responder and PANSS 5-Factor Analyses of a Phase 2 Placebo-Controlled Inpatient Trial